Close menu




December 15th, 2025 | 07:05 CET

The Wall Street leverage: What Bank of America's entry really means for Almonty - the MP Materials blueprint

  • Mining
  • Tungsten
  • Defense
  • Investments
  • hightech
Photo credits: pixabay.com

Capital on the stock market is not all the same. There is "dumb" money that chases short-term trends, and there is "smart" money that actually shapes markets. The alliance between Almonty Industries and Bank of America is therefore far more than a simple financing round. It is an institutional seal of approval that, via access to the wealth management arm Merrill, opens the door to US private capital and enables a re-rating. Analysts such as D.A. Davidson had already confirmed this potential before the most recent capital increase with the high-profile lead bookrunner, issuing concrete price targets of USD 12 and pointing to massive revenue growth through 2028.

time to read: 3 minutes | Author: Nico Popp
ISIN: ALMONTY INDUSTRIES INC. | CA0203987072 , MP MATERIALS CORP | US5533681012

Table of contents:


    Almonty and the mechanism of institutional validation

    In the commodities world, thousands of companies are vying for investors' attention. Most are dependent on expensive venture capital. But Almonty Industries has reached a new phase through its collaboration with Bank of America. To understand the significance of this deal, one must understand the mechanism of "institutional validation," a process already anticipated by leading analysts such as D.A. Davidson and reflected in price targets now firmly in double-digit territory.

    When a major global bank subscribes to a capital increase, it is preceded by extensive due diligence. For the capital markets, this functions as a quality signal. The recent transaction indicates that Almonty's projects and capital structure meet institutional requirements for scale and long-term growth. This assessment has been consistently supported by sell-side research. In its November update, D.A. Davidson reaffirmed its "Buy" rating and increased its price target from USD 11 to USD 12, with other analysts arriving at comparable valuations. These expectations are grounded in operating forecasts rather than sentiment. D.A. Davidson expects Almonty's revenue to explode from an estimated USD 44 million in 2025 to an impressive USD 526 million by 2028. Following the Bank of America transaction, such assumptions have become increasingly accepted within the broader financial community.

    Almonty is a success story in 2025 – and it seems that this story is far from over.

    The Merrill factor - the pipeline to big money

    Perhaps the most important aspect of this partnership lies in the structure of the US financial landscape. Bank of America, through its subsidiary Merrill, is one of the largest asset managers in the world. Once a company like Almonty has received the accolade of a capital increase with Bank of America, the stock potentially becomes investable for Merrill's huge network of advisors. This is capital seeking stability – asset managers for wealthy US clients are looking for both security and opportunities. Almonty increasingly meets these criteria. D.A. Davidson underscores this attractiveness for long-term investors with a forecast for **adjusted EBITDA, which is expected to rise to USD 336 million by 2028. Such profitability makes the stock highly relevant for institutional portfolios that focus on cash flow growth. Since Almonty now has a US listing on the Nasdaq as well as a US mine and a US office, which will become Almonty's headquarters from 2026, the Merrill factor should quickly benefit the stock.

    MP Materials as a blueprint

    MP Materials shows what happens when a Western company gains strategic access to US capital. Investors there pay a premium for geopolitical security. Almonty Industries is heading toward a similar scenario with its tungsten mine in Sangdong. Tungsten is indispensable for the defense and tech industries. According to D.A. Davidson, prices have more than doubled since the beginning of 2025 and have recently risen even further. At the latest fixing in Rotterdam last Friday, the price for APT (ammonium paratungstate, an important intermediate product in tungsten processing) reached an average level of USD 812.50/MTU. As Almonty's CEO recently stated at the International Investment Forum (IIF), mines such as Sangdong are already highly profitable at half that price. Nevertheless, Almonty's stock is significantly undervalued compared to MP Materials and other commodity companies. Back in the fall, Oppenheimer analysts predicted a price-to-earnings ratio (P/E) of around 50 for MP Materials and around 17 for Almonty for 2027. Even uranium producer Cameco achieved a P/E ratio of 45 based on estimated results for 2027.

    The entry of the US financial elite is a clear indication that "smart" capital sees great opportunities in Almonty's stock. When analysts such as Matt J. Summerville of D.A. Davidson raise their price targets and predict a multiplication of EBITDA to over USD 300 million, the discrepancy between the current price and the fundamental value becomes increasingly visible. Ratings are also expected from Almonty's new shareholder base in the coming months. These analyses are likely to point to the existing valuation thesis and expand visibility among US wealth and asset managers, including Merrill's advisory network. Almonty is the only Western company with free delivery capacity for tungsten. While competing projects in Vietnam and Kazakhstan, which will not be able to start production for years anyway, are suffering from delays and high capital requirements, Almonty remains the only alternative. This should soon be reflected even more clearly in the share price.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Armin Schulz on September 30th, 2026 | 10:05 CEST

    Micron, Kobo Resources, MP Materials: Stocks with Upcoming Catalysts in AI, Gold and Rare Earths

    • Mining
    • Gold
    • Africa
    • Commodities
    • Investments
    • RareEarths
    • AI

    The stock market trades on expectations. Between now and the end of the year, three companies across different market segments have upcoming milestones that could reset expectations. Artificial intelligence has significantly fueled demand for memory chips. The quarterly results on September 30 will show how much of that demand is here to stay. A gold explorer is set to release its first mineral resource estimate, revealing how much of the precious metal lies underground. As of January 1, the Pentagon's procurement rules for magnets will become stricter, which could benefit manufacturers with supply chains outside China. We are therefore taking a closer look at Micron Technology, Kobo Resources and MP Materials.

    Read

    Commented by Lars Winter on September 30th, 2026 | 07:50 CEST

    Almonty in Focus, Growth Opportunities at PVA TePla and Redcare Pharmacy: Three Stocks to Watch

    • Tungsten
    • CriticalMetals
    • Pharma
    • Industrial

    Almonty can finally sell tungsten from its South Korean operations, while analysts still see significant upside potential for the stock. PVA TePla aims to double its revenue by 2028. Redcare Pharmacy has raised its forecast once again. Three stocks under the microscope with growth prospects that warrant a closer look.

    Read

    Commented by Stefan Bode on September 30th, 2026 | 07:45 CEST

    Growth Plans Meet Reality: Gerresheimer, Redcare Pharmacy and Volatus Aerospace

    • Drones
    • Defense
    • geopolitics
    • Pharma

    On the stock market, a news item's value is not determined by its headline, but by whether it ultimately translates into sustainable revenue and earnings growth. Three very different business models are therefore facing critical phases over the coming quarters. One industrial company must stabilize margins and investor confidence, a drone specialist needs to scale its order book, and an online retailer must convert growth into profits. The following company updates show where opportunities lie, and which risks the market may already be pricing in.

    Read